Some biotech investors had probably never heard of exosomes until Codiak’s chief executive, Doug Williams, made his pitch at the JP Morgan conference two weeks ago. But the area has been gaining traction, and Jazz’s $56m up-front payment to Codiak is its biggest endorsement to date. Roche and Boehringer Ingelheim have also bought into rival technologies, which broadly seek to use exosomes as delivery vehicles for proteins, small molecules, RNA and other therapeutics. Naturally occurring exosomes are vesicles that bud off from many mammalian cells and are subsequently internalised by other cells, along with their cargo, hence their role in cell-cell communication.
New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties
1 day ago
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
5 days ago
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
26 days ago